Analysis: Warsh rate hike reinforces Fed independence after Trump pressure Americans' incomes rose and poverty fell in 2025, Census Bureau says OpenAI CFO Sarah Friar emphasizes 'need to take safety seriously' on AI risks Elon Musk, the world’s richest man, says he’s living in an Airstream trailer to oversee xAI’s biggest expansion yet Dominant Kerr wins $150K with GB's first Ultimate title Amid war and sanctions, many Iranians are losing their jobs and struggling to get by Dan Chung rebuilt a decimated Alger Management after 9/11. He's still finding the market's winners Kenya's foreign trader crackdown sparks fear among migrant communities OpenAI says it cracked one of math’s grand challenges. But there are troubling questions about how they did it—and what it means for us all U.S. debt is even worse than it seems, and rising Treasury yields are now an ‘all-hands-on-deck situation,’ top economist warns

Michelle Xia

Michelle Xia

Michelle Xia (#3386)

Global Rank #3386
Country Rank #1,033
Country United States

We focus on science and biology and the most advanced technology. I think that makes the difference.

  • $ 1 B
  • Biotech
  • United States
  • F
  • 59 Years

Snapshot

Quick Facts

Global Rank #3,386
Country Rank #1,033
Net Worth $1.0B
Previous Worth $1.0B
Worth Change +$0.0B
Country United States
Industry Biotech
Age 59 Years
Gender F
Worth As Of May 4, 2026
Last Refreshed 11 Sep 2026, 12:00 AM
Residence Zhongshan, China
World Billionaires List United States Billionaires Biotech

Profile Data

Personal Stats

Age 59
Source Of Wealth Biotech, Self Made
Residence Zhongshan, China
Citizenship United States
Education Ph.D, Newcastle University; Bachelor of Science, Sun Yat-sen University
Net Worth Change +$0.0B +0.0% from previous worth
Previous Net Worth $1.0B
Current Net Worth $1.0B

Worth as of May 4, 2026

About Me

Michelle Yu Xia is cofounder, chairwoman and CEO of China-based biotech firm Akeso, which has multiple approved drugs in China to treat cancer. Akeso has captured attention in the biotech world because one of its drugs outperformed Merck's bestseller Keytruda in a head to head Phase 3 trial in 2024. The success of that Akeso drug, ivonescimab, drove up the price of Akeso's shares; the company is listed on the Hong Kong Stock Exchange. Prior to Akeso, Xia worked in research and at U.S. biotech firms for a dozen years starting in the mid 1990s and obtained U.S. citizenship while in America. Akeso licensed its most promising cancer drug to Miami-based firm Summit Therapeutics in 2022 for markets including the U.S., Europe and Japan.

Wealth Growth

Net Worth Growth Over Time

Tracking Michelle Xia's net worth journey over the years, highlighting key growth phases and financial milestones.

© Iconic Billionaires